Literature DB >> 32083328

COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis.

Silvia Angeletti1, Domenico Benvenuto2, Martina Bianchi3, Marta Giovanetti4, Stefano Pascarella3, Massimo Ciccozzi2.   

Abstract

Last December 2019, a new virus, named novel Coronavirus (COVID-2019) causing many cases of severe pneumonia was reported in Wuhan, China. The virus knowledge is limited and especially about COVID-2019 pathogenesis. The Open Reading Frame 1ab (ORF1ab) of COVID-2019 has been analyzed to evidence the presence of mutation caused by selective pressure on the virus. For selective pressure analysis fast-unconstrained Bayesian approximation (FUBAR) was used. Homology modelling has been performed by SwissModel and HHPred servers. The presence of transmembrane helical segments in Coronavirus ORF1ab non structural protein 2 (nsp2) and nsp3 was tested by TMHMM, MEMSAT, and MEMPACK tools. Three-dimensional structures have been analyzed and displayed using PyMOL. FUBAR analysis revealed the presence of potential sites under positive selective pressure (P < .05). Position 723 in the COVID-2019 has a serine instead a glycine residue, while at aminoacidic position 1010 a proline instead an isoleucine. Significant (P < .05) pervasive negative selection in 2416 sites (55%) was found. The positive selective pressure could account for some clinical features of this virus compared with severe acute respiratory syndrome (SARS) and Bat SARS-like CoV. The stabilizing mutation falling in the endosome-associated-protein-like domain of the nsp2 protein could account for COVID-2019 high ability of contagious, while the destabilizing mutation in nsp3 proteins could suggest a potential mechanism differentiating COVID-2019 from SARS. These data could be helpful for further investigation aimed to identify potential therapeutic targets or vaccine strategy, especially in the actual moment when the epidemic is ongoing and the scientific community is trying to enrich knowledge about this new viral pathogen.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  epidemiology; infection; pandemics; pathogenesis; protein-protein interaction analysis; research and analysis methods

Mesh:

Substances:

Year:  2020        PMID: 32083328      PMCID: PMC7228367          DOI: 10.1002/jmv.25719

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


INTRODUCTION

A novel Coronavirus, the COVID‐2019, first appeared in Wuhan, China, last December 2019, spreading in other provinces/regions of China and in many countries other continents. The epidemic originated probably from bat after viral mutation in the spike glycoprotein, as recently suggested, began human‐to‐human transmission. The rapid spread of epidemic generated fear leading China authorities to restrict people movement to and from Wuhan in China, where the first start of epidemic was reported. As of 12 February 2020, 45 206 cases have been documented with 44 687 cases in Mainland China, including 1117 deaths and 5123 recovered https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. The emergence of such a novel, highly virulent pathogen warrants rapid investigation of its etiology and evolution to control the impact on human health. Knowledge about COVID‐2019 is still incomplete, many questions have raised and many answers are needed first of all regarding its pathogenicity, its ability to change, how many people will get sick from each infected person, the so‐called R0 and when infection will be preventable or treatable. In the last period where many researchers are intensively studying the mechanism of COVID‐2019 replication, pathogenicity, and therapeutic strategies, the present study has been realized. The aim was to provide information about how quickly the virus could potentially increase its genetic variability, with important implications for disease progression and drug or vaccine development. At this aim the Open Reading Frame 1ab (ORF1ab) of COVID‐2019 has been analyzed to evidence the presence of mutation caused by selective pressure on the virus and their influence on viral ability to infect human host promoting epidemic spread.

MATERIALS and METHODS

Sequence dataset

The ORF1ab of 15 COVID‐2019 sequences have been downloaded from GISAID (https://www.gisaid.org/) and GenBank (http://www.ncbi.nlm.nih.gov/genbank/) databanks. A dataset has been built using the five sequences of the severe acute respiratory syndrome (SARS) virus and five sequences from Bat SARS‐like virus sharing the highest sequence similarity to the COVID‐2019 sequence (Table 1). The pairwise percentage of similarity has been calculated using Basic Local Alignment Search Tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi); duplicated sequences have been removed from the dataset. The 25 sequences have been aligned using a multiple sequence alignment multiple alignment using fast fourier transform online tool and manually edited using Bioedit program v7.0.5.
Table 1

Accession numbers, virus type, and the archive where they have been taken from

Accession numberVirusSequences archive
EPI_ISL_4039332019‐nCoVGISAID
EPI_ISL_4039342019‐nCoVGISAID
EPI_ISL_4039362019‐nCoVGISAID
EPI_ISL_4039622019‐nCoVGISAID
EPI_ISL_4021322019‐nCoVGISAID
EPI_ISL_4021302019‐nCoVGISAID
EPI_ISL_4048952019‐nCoVGISAID
EPI_ISL_4042532019‐nCoVGISAID
EPI_ISL_4021252019‐nCoVGISAID
EPI_ISL_4021242019‐nCoVGISAID
EPI_ISL_4039302019‐nCoVGISAID
EPI_ISL_4021202019‐nCoVGISAID
EPI_ISL_4021292019‐nCoVGISAID
EPI_ISL_4042282019‐nCoVGISAID
EPI_ISL_4039312019‐nCoVGISAID
MG772933.1Bat SARS‐likeGeneBank
KY417146.1Bat SARS‐likeGeneBank
KT444582.1Bat SARS‐likeGeneBank
KY417147.1Bat SARS‐likeGeneBank
DQ084199.1Bat SARS‐likeGeneBank
AY559093.1SARSGeneBank
JX163925.1SARSGeneBank
GU553365.1SARSGeneBank
JQ316196.1SARSGeneBank
AY714217.1SARSGeneBank

Abbreviations: 2019‐nCoV, novel coronavirus; SARS, severe acute respiratory syndrome.

Accession numbers, virus type, and the archive where they have been taken from Abbreviations: 2019‐nCoV, novel coronavirus; SARS, severe acute respiratory syndrome.

Selective pressure analysis

The selective pressure analysis was focused on the polyprotein ORF1ab because it differs from the most similar bat Coronavirus (QHR63299) for only 103 amino acid residues, 64 of them are conservative changes. In particular, non structural protein 2 (nsp2) differs from bat Coronavirus for 11 residues while nsp3 for 64 residues of which 44 are conservative changes. Adaptive Evolution Server (http://www.datamonkey.org/) was used to find eventual sites under of positive or negative selection pressure. At this purpose the following tests has been used: fast‐unconstrained Bayesian approximation (FUBAR). These tests allowed to infer the site‐specific pervasive selection, the episodic diversifying selection across the region of interest and to identify episodic selection at individual sites. Statistically significant positive or negative selection was based on P < .05.

Structural modelling

Homology modelling has been attempted with SwissModel and HHPred servers. Models for ORF1ab nsp2 and nsp3 proteins available at the I‐Tasser web site (corresponding to codes QHD43415_2 and QHD43415_3) have been considered. PDB Proteins structurally close to the target have been evaluated using the TM‐score while the RAMPAGE online tool has been used to assess the folding quality of the model. To test for the presence of transmembrane helical segments in Coronavirus ORF1ab nsp2 and nsp3, TMHMM, MEMSAT, and MEMPACK online tools have been used. Three‐dimensional structures have been analyzed and displayed using PyMOL.

RESULTS

Regarding the FUBAR analysis performed on the ORF1ab region, the presence of potential sites under positive selective pressure have been found (P < .05), in particular: on the amino acidic position 501 the COVID‐2019 has a glutamine residue, the Bat SARS‐like coronavirus has a threonine residue and the SARS virus has an alanine residue. At position 723 in the COVID‐2019 there is a serine residue while the Bat SARS‐like virus and the SARS virus have a glycine residue. On the aminoacidic position 1010, the COVID‐2019 has a proline residue, the Bat SARS‐like coronavirus has a histidine residue and the SARS virus has an isoleucine residue. Significant (P < .05) pervasive negative selection in 2416 sites (55%) has been evidenced and confirmed by FUBAR analysis. To map the structural variability of the ORF1ab region of the virus and its sites under selection pressure, homology modelling has been attempted. Unfortunately, neither SwissModel nor HHPred found suitable templates for the amino acid region containing the sites under selective pressure. For that reason, the corresponding models available on the I‐Tasser web site has been used. Moreover, some regions of the nsp2 and nsp3 proteins structurally homologous to other known viral proteins have been identified through HHpred analysis and have been mapped within the ORF1ab nsp2 and nsp3 sequences (Figure 1).
Figure 1

A, HHpred mapping of the homologous structures onto the ORF1ab sequence shown as a blue line on the top of the panel. Numbering above the line refers to the entire ORF. Red and Blue strips represent the PDB homologous structures and the nsp2 and nsp3 sequences, respectively. PDB codes are reported within the corresponding red stripes. Numbering below the blue line is relative to each single nsp. Orange lines indicate approximately the positions of the transmembrane helices predicted by MEMSAT. Label refers to panel B. B, diagram of the topology of predicted transmembrane helices. Number refer to the corresponding nsp sequences. nsp, non structural protein; ORF, open reading frame

A, HHpred mapping of the homologous structures onto the ORF1ab sequence shown as a blue line on the top of the panel. Numbering above the line refers to the entire ORF. Red and Blue strips represent the PDB homologous structures and the nsp2 and nsp3 sequences, respectively. PDB codes are reported within the corresponding red stripes. Numbering below the blue line is relative to each single nsp. Orange lines indicate approximately the positions of the transmembrane helices predicted by MEMSAT. Label refers to panel B. B, diagram of the topology of predicted transmembrane helices. Number refer to the corresponding nsp sequences. nsp, non structural protein; ORF, open reading frame The results of the analysis suggest the presence of a segment within the nsp2 and the nsp3 regions that has no evident homologous structures. In an attempt to structurally characterize as far as possible these regions, TMHMM, MEMSAT, and MEMPACK analyses have been utilized and have shown the presence of several potential trans‐membrane helices (Figure 1). In particular, our transmembrane helices were predicted by MEMSAT in nsp2 while six helices were predicted by MEMSTA and TMHMM in nsp3 (Figure 1). Referring to the amino acids under positive selective pressure found using the FUBAR analysis: the amino acid in position 501 (position 321 of the nsp2 protein), the corresponding site in the Bat SARS‐like coronavirus has an apolar amino acid while the SARS and COVID‐2019 has a polar amino acid. It can be speculated, that due to its side chain length, polarity, and potential to form H‐bonds the glutamine amino acid may confer higher stability to the protein. The mutations fall within the protein nsp2 on the region homologous to the endosome‐associated protein similar to the avian infectious bronchitis virus (PDB 3ld1) that plays a key‐role in the viral pathogenicity. (Figure 2) In the nsp2 structure model available at the I‐Tasser site, this position appears to be exposed to the solvent.
Figure 2

I‐Tasser model of the COVID‐2019 nsp2. Residues under positive selective pressure with a P < .05 are shown as sticks and transparent spheres and are marked by the corresponding labels. COVID‐2019, novel Coronavirus; nsp2, non structural protein‐2

I‐Tasser model of the COVID‐2019 nsp2. Residues under positive selective pressure with a P < .05 are shown as sticks and transparent spheres and are marked by the corresponding labels. COVID‐2019, novel Coronavirus; nsp2, non structural protein‐2 As for the residue in position 723 (543 in the nsp3 protein), the COVID‐2019 sequence displays a Ser replacing for Gly in Bat SARS‐like and SARS coronaviruses. In this case, it may be argued that this substitution could increase local stiffness of the polypeptide chain both for steric effect (at variance with Ser, Gly has no side chain) and for ability of Ser side chain to form H‐bonds. Moreover, Ser can act as a nucleophile in determined structural environments, such as those of enzyme active sites. Within the I‐Tasser model, this position is predicted to have a low solvent accessibility (Figure 2). Regarding the amino acid in position 1010 (corresponding to position 192 of the nsp3 protein), the homologous region of the Bat SARS‐like coronavirus and SARS virus have a polar and an apolar amino acid, respectively, while the COVID‐2019 has proline. In this case, it may be speculated that due to the steric bulge and stiffness of the proline, the molecular structure of the COVID‐2019 may undergo a local conformation perturbation compared with the proteins of the other two viruses. In Nsp3, the mutation falls near the protein similar to a phosphatase present also in the SARS coronavirus (PDB code 2acf) playing a key‐role in the replication process of the virus in infected cells (Figure 3). In the I‐Tasser model, the position is partially accessible to the solvent. It should be emphasized that all these considerations are speculative and they need to be substantiated by the availability of the experimental crystallographic structure of the corresponding proteins.
Figure 3

I‐Tasser model of the COVID‐2019 nsp3. The residue under positive selective pressure with a P < .05 is shown as sticks and transparent spheres and is marked by the corresponding label. COVID‐2019, novel Coronavirus; nsp, non structural protein

I‐Tasser model of the COVID‐2019 nsp3. The residue under positive selective pressure with a P < .05 is shown as sticks and transparent spheres and is marked by the corresponding label. COVID‐2019, novel Coronavirus; nsp, non structural protein

DISCUSSION

The COVID‐2019 ongoing epidemic is worrying worldwide for its high contagiosity. From its first appearance in Wuhan, China, about 1 month ago, the virus infected thousands people with new cases number rapidly growing every day. For this acceleration in human‐to‐human transmission in China but with evident spreading also in other countries, World Health Organization declared the epidemic a global health emergency. , Many questions are open and need an answer, of these the most frequent is how much this virus can be dangerous and how much it differs from SARS virus which epidemic scared all the world some years ago. In this study some interesting findings have been evidenced to support and fill gaps in knowledge about the new COVID‐2019 that is still causing infection all over the world. , The positive selective pressure in this protein could justify some clinical features of this virus compared with SARS and Bat SARS‐like CoV. First which are the probably most common sites undergoing to an aminoacidic change, providing an insight of some important proteins of the COVID‐2019 that are involved in the mechanism of viral entry and viral replication. This data can contribute for a better understanding of how this virus acts in its pathogenicity. Furthermore, to identify a potential molecular target is fundamental to follow the molecular evolution of the virus suggesting some interesting sites for potential therapy or vaccine. The structural similarity of the region in which falls the positive selective pressure as so as the stabilizing mutation falling in the endosome‐associated‐protein‐like domain of the nsp2 protein, could explain why this virus is more contagious than SARS. The destabilizing mutation happening near the phosphatase domain of the nsp3 proteins could suggest a potential mechanism differentiating COVID‐2019 from SARS. The results of this study could fill some gaps about COVID‐2019 knowledge especially in the actual moment when the epidemic is ongoing and the scientific community is trying to enrich knowledge about this new viral pathogen. During epidemic, all strength has to be done to enforce virus fight. This can be achieved by understanding the main drivers for pathogen appearance, spreading, and supremacy on human defense.
  21 in total

1.  Evaluation of methods for the prediction of membrane spanning regions.

Authors:  S Möller; M D Croning; R Apweiler
Journal:  Bioinformatics       Date:  2001-07       Impact factor: 6.937

2.  The I-TASSER Suite: protein structure and function prediction.

Authors:  Jianyi Yang; Renxiang Yan; Ambrish Roy; Dong Xu; Jonathan Poisson; Yang Zhang
Journal:  Nat Methods       Date:  2015-01       Impact factor: 28.547

3.  FUBAR: a fast, unconstrained bayesian approximation for inferring selection.

Authors:  Ben Murrell; Sasha Moola; Amandla Mabona; Thomas Weighill; Daniel Sheward; Sergei L Kosakovsky Pond; Konrad Scheffler
Journal:  Mol Biol Evol       Date:  2013-02-18       Impact factor: 16.240

4.  A Completely Reimplemented MPI Bioinformatics Toolkit with a New HHpred Server at its Core.

Authors:  Lukas Zimmermann; Andrew Stephens; Seung-Zin Nam; David Rau; Jonas Kübler; Marko Lozajic; Felix Gabler; Johannes Söding; Andrei N Lupas; Vikram Alva
Journal:  J Mol Biol       Date:  2017-12-16       Impact factor: 5.469

5.  Emerging understandings of 2019-nCoV.

Authors: 
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 6.  Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV.

Authors:  Jia Liu; Xin Zheng; Qiaoxia Tong; Wei Li; Baoju Wang; Kathrin Sutter; Mirko Trilling; Mengji Lu; Ulf Dittmer; Dongliang Yang
Journal:  J Med Virol       Date:  2020-02-21       Impact factor: 2.327

7.  Three Emerging Coronaviruses in Two Decades.

Authors:  Jeannette Guarner
Journal:  Am J Clin Pathol       Date:  2020-03-09       Impact factor: 2.493

8.  Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3.

Authors:  Kumar Singh Saikatendu; Jeremiah S Joseph; Vanitha Subramanian; Tom Clayton; Mark Griffith; Kin Moy; Jeffrey Velasquez; Benjamin W Neuman; Michael J Buchmeier; Raymond C Stevens; Peter Kuhn
Journal:  Structure       Date:  2005-11       Impact factor: 5.006

9.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

10.  COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis.

Authors:  Silvia Angeletti; Domenico Benvenuto; Martina Bianchi; Marta Giovanetti; Stefano Pascarella; Massimo Ciccozzi
Journal:  J Med Virol       Date:  2020-02-28       Impact factor: 2.327

View more
  111 in total

Review 1.  Coronavirus Disease 2019-COVID-19.

Authors:  Kuldeep Dhama; Sharun Khan; Ruchi Tiwari; Shubhankar Sircar; Sudipta Bhat; Yashpal Singh Malik; Karam Pal Singh; Wanpen Chaicumpa; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales
Journal:  Clin Microbiol Rev       Date:  2020-06-24       Impact factor: 26.132

Review 2.  Coronaviruses: What Should We Know About the Characteristics of Viruses?

Authors:  Wei Ji
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.

Authors:  C T Dhanya Raj; Dinesh Kumar Kandaswamy; Ravi Chandra Sekhara Reddy Danduga; Raju Rajasabapathy; Rathinam Arthur James
Journal:  Arch Microbiol       Date:  2021-02-08       Impact factor: 2.552

4.  Antivirals virtual screening to SARS-CoV-2 non-structural proteins.

Authors:  Vinicius S Nunes; Diego F S Paschoal; Luiz Antônio S Costa; Hélio F Dos Santos
Journal:  J Biomol Struct Dyn       Date:  2021-05-05

Review 5.  SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models.

Authors:  G Kanimozhi; B Pradhapsingh; Charan Singh Pawar; Haseeb A Khan; Salman H Alrokayan; N Rajendra Prasad
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 6.  SARS-CoV-2 mutations: the biological trackway towards viral fitness.

Authors:  Parinita Majumdar; Sougata Niyogi
Journal:  Epidemiol Infect       Date:  2021-04-30       Impact factor: 2.451

Review 7.  Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.

Authors:  Idris Nasir Abdullahi; Anthony Uchenna Emeribe; Hafeez Aderinsayo Adekola; Sharafudeen Dahiru Abubakar; Amos Dangana; Halima Ali Shuwa; Sunday Theophilus Nwoba; Jelili Olaide Mustapha; Muyideen Titilope Haruna; Kafayat Adepeju Olowookere; Olawale Sunday Animasaun; Charles Egede Ugwu; Solomon Oloche Onoja; Abdullahi Sani Gadama; Musa Mohammed; Isa Muhammad Daneji; Dele Ohinoyi Amadu; Peter Elisha Ghamba; Nkechi Blessing Onukegbe; Muhammad Sagir Shehu; Chiladi Isomah; Adamu Babayo; Abdurrahman El-Fulaty Ahmad
Journal:  Hum Vaccin Immunother       Date:  2020-09-16       Impact factor: 3.452

Review 8.  The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).

Authors:  Narasimha M Beeraka; SubbaRao V Tulimilli; Medha Karnik; Surya P Sadhu; Rajeswara Rao Pragada; Gjumrakch Aliev; SubbaRao V Madhunapantula
Journal:  Biomed Res Int       Date:  2021-06-01       Impact factor: 3.411

Review 9.  Epidemiological characteristics, reinfection possibilities and vaccine development of SARS CoV2: A global review.

Authors:  Ramakant Yadav; Prashant K Bajpai; Dhiraj K Srivastava; Raj Kumar
Journal:  J Family Med Prim Care       Date:  2021-04-08

Review 10.  SARS coronavirus outbreaks past and present-a comparative analysis of SARS-CoV-2 and its predecessors.

Authors:  Zheng Yao Low; Ashley Jia Wen Yip; Anshika Sharma; Sunil K Lal
Journal:  Virus Genes       Date:  2021-06-01       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.